Janux Therapeutics Inc
NASDAQ:JANX
Income Statement
Earnings Waterfall
Janux Therapeutics Inc
Income Statement
Janux Therapeutics Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
1
+126%
|
2
+135%
|
4
+80%
|
5
+33%
|
7
+39%
|
7
+10%
|
9
+17%
|
9
+5%
|
8
-14%
|
8
+9%
|
8
-5%
|
7
-10%
|
15
+107%
|
13
-14%
|
11
-19%
|
9
-12%
|
0
-95%
|
10
+2 178%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(5)
|
(7)
|
(12)
|
(23)
|
(37)
|
(49)
|
(62)
|
(70)
|
(76)
|
(83)
|
(85)
|
(84)
|
(81)
|
(80)
|
(81)
|
(99)
|
(109)
|
(123)
|
(145)
|
(154)
|
|
| Selling, General & Administrative |
(2)
|
(2)
|
(4)
|
(7)
|
(10)
|
(15)
|
(18)
|
(21)
|
(22)
|
(24)
|
(25)
|
(25)
|
(26)
|
(27)
|
(28)
|
(39)
|
(41)
|
(44)
|
(46)
|
(39)
|
|
| Research & Development |
(3)
|
(4)
|
(8)
|
(16)
|
(26)
|
(35)
|
(44)
|
(49)
|
(53)
|
(59)
|
(60)
|
(58)
|
(55)
|
(53)
|
(53)
|
(60)
|
(68)
|
(79)
|
(99)
|
(115)
|
|
| Operating Income |
(5)
N/A
|
(6)
-30%
|
(11)
-81%
|
(21)
-84%
|
(33)
-56%
|
(44)
-34%
|
(55)
-25%
|
(62)
-13%
|
(67)
-8%
|
(74)
-10%
|
(77)
-5%
|
(75)
+3%
|
(73)
+3%
|
(73)
+0%
|
(66)
+10%
|
(86)
-30%
|
(99)
-15%
|
(114)
-15%
|
(145)
-28%
|
(144)
+0%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(2)
|
(1)
|
0
|
0
|
0
|
0
|
1
|
2
|
4
|
7
|
10
|
13
|
15
|
17
|
22
|
25
|
30
|
36
|
39
|
42
|
|
| Pre-Tax Income |
(7)
N/A
|
(8)
-13%
|
(11)
-49%
|
(21)
-83%
|
(33)
-56%
|
(44)
-34%
|
(54)
-24%
|
(60)
-11%
|
(63)
-4%
|
(67)
-6%
|
(68)
-1%
|
(63)
+8%
|
(58)
+7%
|
(56)
+5%
|
(44)
+21%
|
(61)
-37%
|
(69)
-14%
|
(78)
-13%
|
(106)
-36%
|
(102)
+4%
|
|
| Net Income | |||||||||||||||||||||
| Income from Continuing Operations |
(7)
|
(8)
|
(11)
|
(21)
|
(33)
|
(44)
|
(54)
|
(60)
|
(63)
|
(67)
|
(68)
|
(63)
|
(58)
|
(56)
|
(44)
|
(61)
|
(69)
|
(78)
|
(106)
|
(102)
|
|
| Net Income (Common) |
(7)
N/A
|
(8)
-13%
|
(11)
-49%
|
(21)
-83%
|
(33)
-56%
|
(44)
-34%
|
(54)
-24%
|
(60)
-11%
|
(63)
-4%
|
(67)
-6%
|
(68)
-1%
|
(63)
+8%
|
(58)
+7%
|
(56)
+5%
|
(44)
+21%
|
(61)
-37%
|
(69)
-14%
|
(78)
-13%
|
(106)
-36%
|
(102)
+4%
|
|
| EPS (Diluted) |
-0.17
N/A
|
-0.19
-12%
|
-0.28
-47%
|
-0.51
-82%
|
-0.78
-53%
|
-1.05
-35%
|
-1.31
-25%
|
-1.45
-11%
|
-1.52
-5%
|
-1.62
-7%
|
-1.63
-1%
|
-1.36
+17%
|
-1.32
+3%
|
-1.13
+14%
|
-0.8
+29%
|
-1.1
-38%
|
-1.28
-16%
|
-1.25
+2%
|
-1.7
-36%
|
-1.64
+4%
|
|